多中心试验中急性GVHD的诊断与裁定:BMT CTN 1202生物样本库研究报告
BMT CTN 1202研究纳入1,709例异基因造血细胞移植受者,通过每周数据报告和终点审查委员会(ERC)近实时裁定急性GVHD诊断。症状符合GVHD者占90%,但仅23%在症状起始时考虑GVHD;中心报告累积发病率62%,经ERC裁定仅 probable 或 confirmed 者降至49%。
要点
- 症状起始时仅23%的病例考虑GVHD,提示诊断常被延迟或误判。
- 40%的病例行诊断性活检,但10.5%结果模棱两可,治疗常与活检不符。
- 超过40%的激素疗程因非GVHD原因启动,ERC修正了12.3%的GVHD诊断或分级。
核心结论
- 症状起始时急性GVHD发病率可能被高估,ERC裁定后累积发病率从62%降至49%。
- 研究为急性GVHD建立了当代基准,并提出结构化报告与裁定框架。
研究设计与样本
- BMT CTN 1202为观察性研究,纳入1,709例异基因造血细胞移植受者。
- 采用每周数据报告和终点审查委员会(ERC)近实时裁定,对急性GVHD诊断赋予确认、可能、疑似或阴性置信水平。
主要发现
- 前100天内90%的病例出现符合GVHD的症状,但症状起始时仅23%的病例考虑GVHD。
- 40%的病例行诊断性活检,10.5%的活检结果模棱两可,治疗常与活检发现不符。
- 超过40%的激素疗程因非GVHD原因启动,ERC修正了12.3%的起始病例的GVHD诊断或分级。
- 中心报告的急性GVHD累积发病率为62%,ERC仅将 probable 或 confirmed 裁定为GVHD存在时发病率降至49%。
临床怎么用
- 急性GVHD的诊断应结合活检和临床置信水平,避免仅凭症状起始即启动激素治疗。
- 结构化裁定框架可用于前瞻性试验,提高GVHD诊断和分级的准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate and reproducible methods to diagnose, grade, and report acute graft-versus-host disease (GVHD) are critical for the evaluation of therapies and biomarkers. PATIENTS AND METHODS: The Blood and Marrow Transplant Clinical Trials Network 1202 study is an observational study of 1,709 allogeneic hematopoietic cell transplantation recipients that implemented weekly data reporting and near real-time data adjudication by an end point review committee (ERC), assigning a confidence level (confirmed, probable, possible, or negative) to the diagnosis of acute GVHD at onset. RESULTS: During the first 100 days, symptoms consistent with GVHD developed in 90% of cases but were often determined by centers to be due to causes other than GVHD. Indeed, GVHD was under consideration in only 23% of cases at symptom onset. Diagnostic biopsies were obtained in 40% of cases, but treatment often was incongruous with biopsy findings and 10.5% of biopsies were equivocal. Importantly, more than 40% of steroid courses were started for reasons other than GVHD. The ERC modified the determination of GVHD diagnosis and/or grade in 12.3% of onset cases. The cumulative incidence of acute GVHD as reported by the centers was 62%. When the ERC adjudicated GVHD onset to be present only if the confidence level was probable or confirmed, the incidence of GVHD declined to 49%. CONCLUSION: This study demonstrates that the incidence of GVHD may be overestimated at symptom onset, establishes a contemporary benchmark for acute GVHD, and suggests a structured framework for reporting and adjudication of GVHD that could be used in prospective trials.
引用
- Reshef R, Saber W, Bolaños-Meade J, et al. Acute GVHD Diagnosis and Adjudication in a Multicenter Trial: A Report From the BMT CTN 1202 Biorepository Study. J Clin Oncol. 2021. PMID: 33507810. doi:10.1200/JCO.20.00619
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。